Breast Cancer Chemoprevention Medications

Rodrigo Arrangoiz MS, MD, FACS, FSSO
  • Postmenopausal women with a uterus:
    • Are at a higher risk of developing uterine cancer with tamoxifen:
      • Therefore raloxifene is preferred in this subset
  • Tamoxifen:
    • Provides a slightly higher breast cancer risk reduction compared to raloxifene
  • Raloxifene:
    • Has a slightly lower rate of developing venous thromboembolism (VTE) than tamoxifen
    • It is preferred in patients with osteoporosis
  • Tamoxifen:
    • Is the chemoprevention agent of choice in premenopausal women and in postmenopausal women who have undergone a hysterectomy
  • Aromatase inhibitors:
    • Are another option for chemoprevention and are used:
      • In patients with contraindications to selective estrogen receptor modulator SERM use (history of VTE, stroke risk):
        • But have a significant incidence of musculoskeletal pain and worsening of osteoporosis
  • Fulvestrant, nor leuprolide are used for chemoprevention
  • References:
    • Reimers LL, Sivasubramanian PS, Hershman D, et al. Breast cancer chemoprevention among high-risk women and those with ductal carcinoma in situ. Breast J. 2015;21(4):377-386.
    • Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, Fifth Edition. Philadelphia, PA: Wolters Kluwer Health, 2014.
    • Thorat MA, Cuzick J. Preventing invasive breast cancer using endocrine therapy. Breast. 2017;34(Suppl 1):S47-s54.
Unknown's avatar

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO

My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.

Leave a comment